ロード中...
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis. Upadacitinib is a nonsensitive substrate for metabolism by cytochrome P450 3A enzymes. This open‐label, single‐dose, multicenter study a...
保存先:
| 出版年: | J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766976/ https://ncbi.nlm.nih.gov/pubmed/30973649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1414 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|